Oracle Runs

Will the results be positive?

Trial NCT05831176 (ENGAGE, Regeneron) is active not recruiting with estimated primary completion Feb 2026. No public topline results or readout available as of Apr 2026. Sources confirm ongoing status; other positive dupilumab data in EoG from separate trials (DEGAS NCT03678545) not applicable to this exact trial.

Will the results be positive?

Trial (NCT05831176/ENGAGE, Phase 2 part of 2/3) is active not recruiting with estimated primary completion Feb 2026 (full completion ~Nov 2026). No public readout or results posted on ClinicalTrials.gov or elsewhere; all sources are protocols, descriptions, or refer to separate trials (e.g., DEGAS NCT03678545 with positive histologic/symptom data in EoG). Evidence is pre-results; no trial-specific positive/negative framing.

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Will the results be positive?

No trial-specific public efficacy readout was found for NCT05831176. The exact study remains listed as active/ongoing on ClinicalTrials.gov, and Sanofi’s pipeline materials still listed ENGAGE as an active main clinical study rather than reporting results. That is insufficient to call the Phase 2 outcome positive or negative.

Will the results be positive?

No trial-specific public efficacy readout was found. Sponsor materials still list ENGAGE/NCT05831176 as an active clinical study, and an FDAAA tracker page shows the trial as ongoing with no actual results date posted. Without a public readout, the outcome cannot be classified positive or negative.